IN THE FOOTSTEPS OF ROBERT BOYLE. New Ways Of Organising Drug Discovery By Dr. Bernard Leddy PhD MPSI.

Slides:



Advertisements
Similar presentations
Gakava L Roche Products Ltd., Welwyn, UK
Advertisements

UKRDS Conference 26 February 2009 A Researchers Perspective: the Value and Challenge of Data Professor John Coggins Vice Principal, Life Sciences & Medicine.
Stormont Castle 9 th May, 2012 Overview Housing in Rep. of Ireland – Challenges and opportunities NABCO – About Us Continuing Delivery Co-operative Living.
The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.
Efficiency, Ethics and Cost in Pharmaceutical Research and Manufacturing Matthew Wirtala Spring 2006.
CUHP Cambridge University Health Partners (CUHP) unites a world-leading University and three high- performing NHS Foundation Trusts centred on the Cambridge.
Powder Changes of Theoretical and Experimental Pharmacology Teaching in Xi’an Zang Wei-jin Department of Pharmacology School of Medicine, Xi’an Jiaotong.
Philip J. Ditchfield Manager, Contracts & Licensing GlaxoSmithKline Data Mining and the Pharmaceutical Industry.
Academia, Healthcare Providers, and the Industry Three Different Worlds? Three Different Sets of Goals? Sheldon Kong, PhD Senior Director, Outcomes Research.
GIS AND PUBLIC HEALTH Jeff Jones, PhD, UK College of Public Health.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
PHARMACOECONOMICS and RATIONAL DRUG USE DRAFT PROGRAM FOR 1 st ISPOR INTERNATIONAL SUMMER SCHOOL ISPOR SCP (TURKEY) ANTALYA, APRIL 17-21, 2008 PHARMACOECONOMICS.
Pharmaceuticals: Lecture Outline Introduction 1.Historical Development of Pharmaceuticals 2. Modern Uses & Canadian Health Care 3. Doctors & Pharmaceuticals.
Paying Less By Purchasing Smarter Gerard Anderson, PhD Professor Johns Hopkins University.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Functional Areas within Business
Pharmacy at Manchester Pharmacy at Manchester Dr Antony D’Emanuele, Senior Lecturer Dr Rachel Elliott, Clinical Lecturer School of Pharmacy and Pharmaceutical.
Role of Advanced Manufacturing in the Future U.S. Economy Yung C. Shin Donald A. & Nancy G. Roach Professor of Advanced Manufacturing Purdue University.
The New Economic Landscape Brian W Tempest CEO & Managing Director Ranbaxy Laboratories Limited, India The Pharmaceutical Industry in the 21 st Century.
Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest CpHI Ramada Hotel, Berlin, Germany 11 September 2013.
GCE AS in Applied ICT Unit 2 How organisations use ICT 2. Functions within Organisations Tom Robinson
Technology Strategy Innovation Platforms Allan Mayo Technology Strategy Directorate DTI.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Checks on Other Branches In many states the legislature must approve officials and judges appointed by the governor. They also examine how well executive.
Drug Trade and Illegal Immigrants Zach Boyle Mackenzie Cole Tyler Wineke.
Negative effects of Outsourcing Tommy Wu. Why Outsource?  Labour costs are the biggest expense in business.  In the 21 st century, we began to reduce.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
Innovating out of the recession in the NHS Steve Barnett, Chief Executive NHS Confederation 28 th October 2009 Foundation Trust Network - Primary Care.
The Physician - Pharma Relationship.  Is very old and very close  But are the goals of pharmaceutical companies and medicine the same?
Market Segment Training. AA ~$2,000M* GC ~$1,650M* Biotech ~$7,500M* Liquid ~$4,100M* (growth at ~6% per annum) *based on figures from SDI 2004 All prices.
The Olympic Games London 2012 Benefits Current view of the Olympic Stadium.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
Current Landscape of Healthcare Reform Legislation 2009 (Last Updated: August 13, 2009)
Confidential and Proprietary Information © 2014 Express Scripts Holding Company. All Rights Reserved. 1 Confidential and Proprietary Information © 2014.
Delivering research to make patients, and the NHS, better Introduction to the Research Ready Accreditation Kelly Adams, Cross Divisional Support Manager,
NoWCADD Progress Report 2015
Unit 10.  Every year millions of new business ideas are developed worldwide. In the past successful business ideas developed by small startup business.
1 Destination India: Contract Research in Pharmaceuticals & Healthcare S.P. Vasireddi, Ph.D Chairman, ACRO 26/03/2009.
A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.
© 2012 IP Technology Exchange, Inc.1 What does a small/medium Pharma-Biotech need to do to get on “Big Pharma’s” radar? Mark McBride Managing Director,
Health Policy Issues An Economic Perspective Copyright © 2015 Foundation of the American College of Healthcare Executives. Not for sale.
Your Doctor Is WRONG... Alzheimer's Can Be Reversed Doctors Tell Us That Alzheimer's And Other Forms Of Dementia Can't Be Reversed. "They Can't Be Cured",
Darragh O’Loughlin MPSI IPU Secretary General Irish Pharmaceutical Healthcare Association RDS, Dublin: 26 November 2013.
The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023 “Global Cancer Drugs And Treatments Market will reach $143.7bn by 2023” Published.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Developing and Broadening Specialists in Research & Development
I am in the Biotechnology industry
Professor Graham Stokes
SWOT analysis.
Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.
The challenge of clinician and health system leadership
SWOT ANALYSIS.
Free Trade and Intellectual Property Rights: Implications for the Canadian Pharmaceutical Environment Joel Lexchin MD School of Health Policy & Management.
REIMAGING PHARMACEUTICAL INNOVATION.
A journey through drug discovery The life cycle of a new medicine
SWOT analysis.
Der Mittelstand (The German Middle Order companies)
Future Innovations Seminar
Dr. Christopher Hentschel
A glimpse to the future: The ARV pipeline up to how do we ensure it is affordable and acceptable? Helen McDowell Head of Government Affairs & Global.
Commonalities across treatments and diseases: A brief overview
Croatia, Zagreb, September 4, 2018 Ljiljana Sović Brkičić
Croatia, Zagreb, June 29, 2018 Ljiljana Sović Brkičić
A2 Operations Management
Solid State Pharmaceutical Centre ( )
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

IN THE FOOTSTEPS OF ROBERT BOYLE. New Ways Of Organising Drug Discovery By Dr. Bernard Leddy PhD MPSI

Robert Boyle ( ) Father of Modern Chemistry

Lismore Castle

Lismore County Waterford

Boyle’s Air Pump

Reality Of Job Losses 7300 Jobs Lost Worldwide 2400 Jobs Lost U.K Jobs Lost U.S.A. 300 Jobs Lost Ireland.

Dr. John Dixon ‘’ A Business Model for UK Drug Discovery’’..’  ’Contractions raise Worldwide concerns since expectations for new medicines exists everywhere. They must be innovative, affordable and usually suitable for oral delivery. In general only small molecules provide this on a Worldwide basis’’.  ‘’ widespread Medicinal Chemistry outsourcing brings similar threats’’

Professor Joel Lexchin from York University, Toronto, Canada  The real innovation crisis is that Pharmaceutical Research and development turns out mostly minor variations on existing drugs‘’  more money is spent on promotion (25%) than on discovering new drugs (1.3%).  the remuneration of drug companies for their R&D should move to a model where companies increase their revenue by producing products that provide meaningful gains in health outcomes

Consider This… “GlaxoSmithKline is to pay $3bn in fines, in what is the largest healthcare fraud settlement in US history.” July “GlaxoSmithKline to buy Maryland- based company for $3 billion” July 2012.

What a Network Should Look Like.

What The Patent Cliff Looks Like

New Uses For Old Drugs Thalidomide

S isomer Teratogen

Professor Dakshanamurthy  developed a rational system for analysing the molecular structure of old, already licensed, drugs for potential new uses.  His system called Train Match Fit Streamline or TMFS for short  examine 11 parameters of drug structure in a way which characterises potential pharmacological activity.

Conclusion  We must now try and look at the World,as Boyle had to in the 17th. Century, from a completely new perspective.  We need to work together with a common purpose using the resources of the  Big Pharma companies,  the well endowed research foundations,  ancient Universities and new,  big research departments and small  linked through a network of mutual support and co- operation to ensure the future development of novel Pharmaceuticals.